Sontaya Sookying, Dumrongsak Pekthong, AM Oo-puthinan, Jie Xing, Zhaoqi Zhan, Kornkanok Ingkaninan
Bioscreening Unit, Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmaceutical Sciences
and Center of Excellence for Innovation in Chemistry, Naresuan University, Phitsanulok 65000, Thailand.
Bacopaside I, a major chemical constituent of Bacopa monnieri (L.), is reported to be responsible for neuropharmacological
effects. The study on its pharmacokinetics has not been reported until today. To study the metabolism of bacopaside I, in the
present study we aimed at finding a rapid and sensitive method for determination of this compound in rat plasma, urine and
feces. In this experiment, the LCMS-IT-TOF method was developed and validated for the determination of bacopaside I in rat
urine. The method was proved to be accurate, precise, specific and has been successfully applied to the metabolism study in a
rat model. Both LOD and LOQ were lower than 4.8 ng/ml. The calibration curves showed good linearity. The curve coefficient
was 0.999. The precision values, expressed as CV, were less than 15% at all concentrations within the standard curve.
Percentage accuracies were in the range of 85-115%. The extraction recoveries of bacopaside I from the samples were all in the
acceptable range. All the results suggested that LCMS-IT-TOF method was suitable for quantitative analysis of bacopaside I in
urine samples. However, the methods for determination of bacopaside I in plasma and feces still have to be validated. The
results from the preliminary study revealed that most of bacopaside I was excreted in rat feces at the period of 12 to 18 h after
oral administration. More than 2.3% of the administered dose was excreted in feces within 42 h after the administration. There
was no bacopaside I represented in urine and feces samples. The transformation and/or metabolism of the compound are